Can coenzyme Q10 prevent statin side effects?

A Mayo Clinic specialist discusses the use of coenzyme Q10 to prevent statin side effects.
Source: MayoClinic.com - Ask a Specialist - Category: Consumer Health News Source Type: news

Related Links:

This study demonstrates how variables besides coexisting medical diseases can affect surgical outcomes. Metformin now joins β-blockers, statins, and immunonutrition as preoperative agents associated with improved surgical outcomes. It may be only a matter of time before optimization of postoperative outcomes with perioperative medications and supplements becomes a standard. To answer this question more completely, furth er analysis or future trials should factor in statin use, as well as whether medications are continued in the postoperative period.
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
AbstractCurrent coronavirus pandemic named coronavirus disease 2019 (COVID ‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). SARS‐CoV‐2 is the third coronavirus outbreak during the current century after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.1 Acute respiratory distress syndrome (ARDS) is an immunopathologic event and main cause of death following COVID ‐19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), in...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: LETTER TO THE EDITOR Source Type: research
Purpose of review With the exception of familial hypercholesterolaemia, the value of genetic testing for managing dyslipidaemias is not established. We review the genetics of major dyslipidaemias in context of clinical practice. Recent findings Genetic testing for familial hypercholesterolaemia is valuable to enhance diagnostic precision, cascade testing, risk prediction and the use of new medications. Hypertriglyceridaemia may be caused by rare recessive monogenic, or by polygenic, gene variants; genetic testing may be useful in the former, for which antisense therapy targeting apoC-III has been approved. Familial hi...
Source: Current Opinion in Cardiology - Category: Cardiology Tags: MOLECULAR GENETICS: Edited by Ali J. Marian Source Type: research
PMID: 32250699 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Publication date: Available online 5 April 2020Source: Canadian Journal of CardiologyAuthor(s): Michael Khoury, Brian W. McCrindle
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
A friend of mine takes a statin medication each day to lower his cholesterol. More than once I’ve heard him say “I ate too much! I’m going to have to take an extra pill.” Never mind that it doesn’t work that way — a single additional statin pill won’t make much difference to his cholesterol or his health. And never mind that you shouldn’t self-adjust the dose of your medications (talk to your doctor before making any changes in medication dosing). But my friend’s overindulging does bring up the question of whether starting medications for conditions like high blood pres...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Exercise and Fitness Health Healthy Eating Heart Health Hypertension and Stroke Source Type: blogs
Authors: Wójcik C Abstract Atherosclerotic cardiovascular disease (ASCVD) is the main cause of morbidity and mortality in the US. ASCVD is caused by elevated levels of ApoB lipoproteins, which over many years penetrate the arterial subendothelial space leading to plaque growth and eventually rupture causing clinical symptoms. ApoB lipoprotein levels are approximated in clinical practice by LDL-C measurement. LDL-C lowering agents (statins, ezetimibe and PCSK9 inhibitors) reduce cardiovascular risk in primary and secondary prevention proportionally to LDL-C reduction (23% per 1 mmol/L of LDL). However, for a ...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
Authors: Wan Q, Qian S, Huang Y, Zhang Y, Peng Z, Li Q, Shu B, Zhu L, Wang M Abstract Cardiovascular disease is the number one cause of human morbidity and mortality worldwide. Although cholesterol-lowering drugs, including statins and recently approved PCSK9 inhibitors, together with antithrombotic drugs have been historically successful in reducing the occurrence of coronary artery disease (CAD), the high incidence of CAD remains imposing the largest disease burden on our healthcare systems. We reviewed cardiovascular drugs recently approved or under clinical development, with a particular focus on their pharmaco...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Xu RX, Wu YJ Abstract Coronary artery disease (CAD) is one of the leading causes of death worldwide. It is well known that dyslipidemia is a major pathogenic risk factor for atherosclerosis and CAD, which results in cardiac ischemic injury and myocardial infarction. Lipid-modifying drugs can effectively improve lipid abnormalities including reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) or increasing high-density lipoprotein cholesterol (HDL-C), and eventually decrease the incidence of cardiovascular events. This chapter will review basic principles of lipid metabolism and focu...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Jia S, Liu Y, Yuan J Abstract In this chapter, we focus on evidences in current guidelines for treatment of coronary artery disease (CAD). In Part 1, diet and lifestyle management is discussed, which plays an important role in CAD risk control, including forming healthy dietary pattern, maintaining proper body weight, physical exercise, smoking cessation, and so on. Part 2 elaborated on revascularization strategies and medical treatments in patients presenting with acute coronary syndrome (ACS), including specific AHA and ESC guidelines on ST elevation myocardial infarction (STEMI) and non-ST elevation ACS...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Cholesterol | Health | Statin Therapy